BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu

TYK2 Inhibitor Grows Bristol’s Immunology Franchise

 
• By Mandy Jackson
  
Start up concept with businessman holding briefcase and standing in front of rocket shaped gap in wall, revealing sunlit New York city view
BMS hired a whole new dermatology sales team to market Sotyktu • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip